Abstract

BackgroundIrinotecan is used as second-line treatment in advanced gastric or gastroesophageal junction (G/GEJ) cancer. The role of anti-programmed death-1 (PD-1) antibody plus irinotecan, in this setting and population is unclear.MethodsThis...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer.
Jianzheng Wang ... Yunduan He
Frontiers in Oncology | VOL. 12
Jianzheng Wang, et. al.Jianzheng Wang ... Yunduan He
01 Jun 2022
Immune Checkpoint Inhibitor Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Review and Meta-Analysis.
Lianghui Zhang ... Tao Ling
Technology in Cancer Research and Treatment | VOL. 23
Lianghui Zhang, et. al.Lianghui Zhang ... Tao Ling
01 Feb 2024
HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.
Yan Song ... Xianli Yin
Journal of Clinical Oncology | VOL. 38
Yan Song, et. al.Yan Song ... Xianli Yin
20 May 2020
Systematic literature review and meta-analysis of clinical outcomes for previously treated patients with advanced gastric or gastroesophageal junction cancer.
Lauren Abderhalden ... Ali Mojebi
Journal of Clinical Oncology | VOL. 40
Lauren Abderhalden, et. al.Lauren Abderhalden ... Ali Mojebi
01 Jun 2022
View more papers

More From: Journal for ImmunoTherapy of Cancer

Paper Title
Journal
Date
Author
EphA3 CAR T cells are effective against glioblastoma in preclinical models
Paulo Martins ... Rajiv Khanna
Journal for Immunotherapy of Cancer | VOL. 12
Paulo Martins, et. al.Paulo Martins ... Rajiv Khanna
07 Aug 2024
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses
Leesa Lertsumitkul ... Misty R Jenkins
Journal for Immunotherapy of Cancer | VOL. 12
Leesa Lertsumitkul, et. al.Leesa Lertsumitkul ... Misty R Jenkins
07 Aug 2024
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
Michael Schenker ... Massimo Di Nicola
Journal for Immunotherapy of Cancer | VOL. 12
Michael Schenker, et. al.Michael Schenker ... Massimo Di Nicola
06 Aug 2024
Targeting tumor-associated macrophage-derived CD74 improves efficacy of neoadjuvant chemotherapy in combination with PD-1 blockade for cervical cancer
Zixiang Wang ... Baoxia Cui
Journal for Immunotherapy of Cancer | VOL. 12
Zixiang Wang, et. al.Zixiang Wang ... Baoxia Cui
06 Aug 2024
View more papers